TP53 and prostate carcinoma: Nevertheless, individual analyses of these HRR mutations showed that TP53 mutation was associated with high HRD scores (Figure 3, p = 0.031), which has also been reported in colorectal and prostate cancer ((Smeby et al., 2020; Lotan et al., 2021).